Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered ...
A new Cedars-Sinai Cancer study shows that patients with advanced liver cancer who receive immunotherapy to shrink their ...
Pivotal Phase III liver cancer study enrolling in Europe and Israel RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ...
“The biggest risk for lung cancer is cigarette smoking,” says Waqar. It’s estimated that 85% of lung cancer deaths are ...
Colon cancer, also known as colorectal cancer, is one of the most frequent and aggressive cancers. According to the WHO, it ...
The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.
Dr Moni Abraham Kuriakose –co-founder, medical director, and CEO of Karkinos Kerala – is a leading surgical oncologist and ...
Conclusions TACE plus targeted immunotherapy yields high response and surgical conversion rates with acceptable toxicity in uHCC. Patients with CNLC stage Ib–IIa, <3 tumors, no major vascular invasion ...
Liver cancer is often diagnosed at an advanced stage, when tumors are too large for a transplant or removal. Immunotherapy, ...
Pancreatic cancer is projected to be the second leading cause of cancer deaths by 2030, but experts say Ireland is failing ...
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...
The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback